ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Effects of perioperative MESNA on lipid peroxidation and myocardial injury in patients undergoing coronary artery bypass grafting: a randomized, double-blind, placebo-controlled trial.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oxidative stress is a major contributor to myocardial injury following coronary artery bypass grafting (CABG). MESNA (sodium 2-mercaptoethane sulfonate), a thiol-containing antioxidant, has demonstrated potent free radical scavenging properties. This study evaluated the effects of perioperative MESNA administration on oxidative stress, myocardial injury biomarkers, and early postoperative cardiac function in patients undergoing elective on-pump CABG. In this randomized, double-blind, placebo-controlled trial, 100 adults undergoing elective isolated CABG with cardiopulmonary bypass were randomly assigned (1:1) to receive intravenous MESNA (1600 mg) or placebo. The primary outcome was postoperative oxidative stress assessed by serum malondialdehyde (MDA). Secondary outcomes included cardiac troponin I (cTnI), creatine kinase-MB (CK-MB), and left ventricular ejection fraction (LVEF). Baseline MDA concentrations were comparable between groups. MESNA significantly reduced postoperative MDA concentrations over the first 24 h compared with placebo (group-by-time interaction, P < 0.001). CK-MB concentrations were significantly lower in the MESNA group, with an estimated between-group difference of - 22.42 U/L at 24 h (P = 0.001). In contrast, cTnI concentrations did not differ significantly between groups. Patients receiving MESNA had higher LVEF at hospital discharge, and this association remained significant after multivariable adjustment (adjusted β = 2.93, 95% CI 0.98-4.87; P = 0.004). No treatment-related adverse events were observed. In patients undergoing elective on-pump CABG, perioperative administration of MESNA was associated with reduced postoperative lipid peroxidation, lower CK-MB release, and improved early postoperative ventricular function. Larger multicenter studies are needed to confirm these findings and their clinical significance.
Indexed as
Identifiers
42717113What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.